MASM
VKTX icon

MH & Associates Securities Management’s Viking Therapeutics VKTX Stock Holding History

MH & Associates Securities Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.54M Sell
65,180
-242
-0.4% -$7.82K 2.28% 23
2026
Q1 		$2.13M Buy
65,422
+21,788
+50% +$700K 1.86% 28
2025
Q4 		$1.54M Buy
+43,634
New +$1.55M 1.25% 37

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

MH & Associates Securities Management's VKTX Position: Q2 2026 in Review

MH & Associates Securities Management reduced its Viking Therapeutics (VKTX) stake by 0.37% in Q2 2026, selling an estimated $7.82K and leaving 65,180 shares worth $2.54M. The position accounts for 2.28% of the portfolio, ranked #23.

MH & Associates Securities Management first reported a position in VKTX in Q4 2025 and has held it in 3 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • MH & Associates Securities Management held 65,180 shares of Viking Therapeutics worth $2.54M as of Q2 2026.
  • MH & Associates Securities Management sold 242 Viking Therapeutics shares in Q2 2026, an estimated $7.82K.
  • Viking Therapeutics made up 2.28% of MH & Associates Securities Management's portfolio in Q2 2026, its #23 holding.
  • MH & Associates Securities Management first reported a position in Viking Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on MH & Associates Securities Management's 13F filing for Q2 2026, filed 28 Jul 2026.